

Brand Institute is proud to have partnered with 900+ healthcare companies on over 3,300 pharmaceutical brand names, highlighted by these most recent name approvals from Japan's MHLW

PLEASE BE SAFE AND THANK YOU FOR MAKING  
 BRAND INSTITUTE THE WORLD'S #1 NAMING COMPANY!

<p>March 25, 2020</p>  <p><b>Viltepso®</b>                  (viltolarsen) injection                  ビルテプソ</p>	<p>March 25, 2020</p>  <p><b>ENHERTU®</b>                  fam-trastuzumab deruxtecan-nxki                  20 mg/mL INJECTION FOR INTRAVENOUS USE                  エンハーツ</p>	<p>March 25, 2020</p> <p><b>VELEXBRU</b>                  tirabrutinib                  ベレキシブル</p>
<p>March 25, 2020</p>  <p><b>Latuda®</b>                  (lurasidone HCl) tablets                  ラツーダ</p>	<p>March 25, 2020</p>  <p><b>vonvendi</b>                  [von Willebrand factor                  (Recombinant)]                  ボンベンディ</p>	<p>March 25, 2020</p> <p><b>CABPIRIN</b>                  Vonoprazan fumarate, aspirin                  キャブピリン</p>
<p>March 25, 2020</p>  <p><b>CABOMETYX®</b>                  (cabozantinib) tablets                  カボメティクス</p>	<p>March 25, 2020</p>  <p><b>Beovu®</b>                  (brolucizumab-dbil)                  Injection                  ベオビュ</p>	<p>January 23, 2020</p>  <p><b>DAYVIGO</b>                  (lemborexant) (IV) 5mg, 10mg tablets                  デエビゴ</p>
<p>January 23, 2020</p>  <p><b>NUBEQA®</b>                  (darolutamide) 300 mg tablets                  ニュベクオ</p>	<p>January 14, 2020</p>  <p><b>Dovato</b>                  dolutegravir 50 mg/                  lamivudine 300 mg tablets                  ドウベイト</p>	<p>January 14, 2020</p>  <p><b>Pifeltro®</b>                  doravirine                  ピフェルトロ</p>

**DRUG SAFETY INSTITUTE (DSI) NAMING & LABELING EXPERT SPOTLIGHT**



**Todd Darwin Bridges, R. Ph.**

Global President  
 Drug Safety Institute

Mr. Bridges joined DSI - Rockville in May 2018 as Global President. Prior to joining DSI, Mr. Bridges was the Director of the Division of Medication Error Prevention and Analysis (DMEPA) in the Office of Surveillance and Epidemiology at the U.S. Food and Drug Administration (FDA). He has more than thirteen years of DMEPA experience with three of those years as the Director of DMEPA.

As Director of DMEPA, Mr. Bridges was responsible for supervising the premarket review and approval of proposed proprietary/brand drug names, labels/labeling, packaging, product design, United States Adopted Names, biological product proper name suffixes, and human factors studies in order to reduce the potential for medication errors with products regulated by the Center for Drug Evaluation and Research (CDER). DMEPA conducts review and analysis of post-marketing medication errors submitted to CDER to determine if regulatory action such as label/labeling revisions, names change, product redesign, or post-marketing communications to stakeholders is needed. DMEPA also works with external stakeholders, regulators, and researchers to better understand the causes of medication errors and the effectiveness of interventions at preventing them, and provides guidance to the pharmaceutical industry on drug development considerations from a medication errors perspective.

Mr. Bridges has contributed to FDA policy and guidances related to medication errors, represented FDA as a member of the National Coordinating Council for Medication Error Reporting and Prevention as well as the Joint Commission's Patient Safety Advisory Group, and was responsible for establishing FDA's ongoing membership with the International Medication Safety Network. In addition to his FDA experience, Mr. Bridges has thirteen years of pharmacy practice and supervisory experience prior to joining FDA. He has also received specialty training in medication error prevention and analysis from the Institute for Safe Medication Practices.

Mr. Bridges earned a B.S. in Pharmacy from Virginia Commonwealth University's Medical College.



**Nora Roselle, Pharm.D.**


President, U.S. Regulatory Affairs  
 Drug Safety Institute

Dr. Roselle joined DSI - Rockville as Managing Director of U.S. Regulatory Affairs in 2007, promoted in 2012 to Vice President, Global Regulatory Affairs and most recently promoted to President, U.S. Regulatory Affairs. Prior to DSI, she served as an officer (LCDR) in the U.S. Public Health Service. She joined the U.S. Food and Drug Administration (FDA) in 2001 as a Safety Evaluator in the Division of Medication Errors and Technical Support (DMETS), in the Office of Drug Safety (ODS), renamed the Office of Surveillance and Epidemiology (OSE), now known as the Division of Medication Error

Prevention and Analysis (DMEPA). DMEPA is responsible for the approval of manufacturer's drug/biologic brand names and human factors/ medication error evaluation of drug and drug/device labeling, packaging, and product design to reduce medication errors.

As Team Leader, Dr. Roselle managed DMETS safety evaluators, proprietary (brand, line extension, and combination product) name reviews, labeling and risk management consults. Dr. Roselle has published several articles on medication errors. Two of her most widely known name safety articles include "Metadate ER or Metadate CD?; Drug Topics 2004, Oct 11:62,64" and "Confusion between Methylphenidate and Methadone, Patient Care 2003, Jan 15:76." Dr. Roselle earned a Doctor of Pharmacy from the University of Maryland (with Honors) and a B.S. in Biology with a Chemistry Minor from the University of Akron (Cum Laude).

**BRAND INSTITUTE'S 2020 GLOBAL SHARE OF MARKET NAME APPROVALS**



**Corporate Headquarters**

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL	BOSTON	CHICAGO	DALLAS	FRANKFURT	LONDON	LOS ANGELES	MIAMI	NEW YORK
+41 78-879-4619	(781) 602-6044	(312) 475-9600	(512) 369-9100	+49 6196-400-966	+44 207-240-2200	(310) 830-6111	(305) 984-6889	(212) 557-2100
OTTAWA	RALEIGH-DURHAM	ROCKVILLE	SAN FRANCISCO	SÃO PAULO	SEATTLE	SEOUL	TOKYO	TORONTO
(613) 482-1333	(919) 572-9311	(301) 984-1055	(415) 421-3200	+55 11 945-364-083	(206) 204-5111	+82 6433-9555	+81(03) 6861-7517	(416) 622-5777